0.00
price down icon100.00%   -131.87
after-market After Hours: 131.92 131.92 +
loading
Intra Cellular Therapies Inc stock is traded at $0.00, with a volume of 0. It is down -100.00% in the last 24 hours and down -100.00% over the past month.
See More
Previous Close:
$131.87
Open:
$0
24h Volume:
0
Relative Volume:
0.00
Market Cap:
$14.05B
Revenue:
$612.78M
Net Income/Loss:
$-86.37M
P/E Ratio:
0.00
EPS:
-0.87
Net Cash Flow:
$-62.91M
1W Performance:
-100.00%
1M Performance:
-100.00%
6M Performance:
-100.00%
1Y Performance:
-100.00%
1-Day Range:
Value
$0.00
$0.00
1-Week Range:
Value
$0.00
$0.00
52-Week Range:
Value
$0.00
$131.98

Intra Cellular Therapies Inc Stock (ITCI) Company Profile

Name
Name
Intra Cellular Therapies Inc
Name
Phone
(646) 440-9333
Name
Address
135 ROUTE 202/206, BEDMINSTER, NY
Name
Employee
0
Name
Twitter
Name
Next Earnings Date
2024-10-30
Name
Latest SEC Filings
Name
ITCI's Discussions on Twitter

Compare ITCI with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Drug Manufacturers - Specialty & Generic icon
ITCI
Intra Cellular Therapies Inc
0.00 14.05B 612.78M -86.37M -62.91M -0.87
Drug Manufacturers - Specialty & Generic icon
ZTS
Zoetis Inc
157.44 68.46B 9.26B 2.49B 2.30B 5.47
Drug Manufacturers - Specialty & Generic icon
TAK
Takeda Pharmaceutical Co Adr
15.32 47.30B 30.25B 1.37B 5.08B 0.4257
Drug Manufacturers - Specialty & Generic icon
HLN
Haleon Plc Adr
10.70 45.89B 14.35B 1.85B 0 0.4023
Drug Manufacturers - Specialty & Generic icon
TEVA
Teva Pharmaceutical Industries Ltd Adr
16.19 17.90B 16.54B -1.64B 749.00M -1.45
Drug Manufacturers - Specialty & Generic icon
UTHR
United Therapeutics Corp
294.60 13.14B 2.76B 1.11B 898.10M 22.77

Intra Cellular Therapies Inc Stock (ITCI) Upgrades & Downgrades

Date Action Analyst Rating Change
Feb-24-25 Downgrade Mizuho Outperform → Neutral
Jan-31-25 Downgrade Canaccord Genuity Buy → Hold
Sep-06-24 Upgrade Piper Sandler Neutral → Overweight
Jan-03-24 Initiated Robert W. Baird Outperform
Dec-11-23 Initiated TD Cowen Outperform
Apr-20-23 Initiated Morgan Stanley Overweight
Aug-22-22 Downgrade Goldman Buy → Neutral
Jul-07-22 Initiated Mizuho Buy
Jun-14-22 Initiated UBS Buy
Apr-22-22 Initiated Piper Sandler Neutral
Feb-16-22 Initiated Goldman Buy
Sep-23-21 Initiated Needham Buy
Dec-15-20 Initiated BofA Securities Buy
Dec-10-20 Initiated Goldman Buy
Feb-20-20 Initiated Evercore ISI Outperform
Jan-31-20 Downgrade JP Morgan Overweight → Neutral
Dec-24-19 Reiterated Canaccord Genuity Buy
Aug-12-19 Initiated Jefferies Buy
Feb-26-18 Initiated JP Morgan Overweight
Feb-08-18 Initiated RBC Capital Mkts Outperform
Dec-15-17 Initiated Canaccord Genuity Buy
Nov-08-17 Upgrade SunTrust Hold → Buy
Sep-07-17 Upgrade Piper Jaffray Neutral → Overweight
Aug-30-17 Upgrade Ladenburg Thalmann Neutral → Buy
Aug-24-17 Upgrade JMP Securities Mkt Perform → Mkt Outperform
Aug-23-17 Upgrade Leerink Partners Mkt Perform → Outperform
May-02-17 Downgrade Ladenburg Thalmann Buy → Neutral
May-02-17 Downgrade Leerink Partners Outperform → Mkt Perform
May-01-17 Downgrade Piper Jaffray Overweight → Neutral
Dec-16-16 Initiated Cantor Fitzgerald Overweight
Sep-29-16 Reiterated RBC Capital Mkts Outperform
Sep-29-16 Downgrade SunTrust Buy → Neutral
View All

Intra Cellular Therapies Inc Stock (ITCI) Latest News

pulisher
01:00 AM

Dealmaking Quarterly Statistics, Q1 2025 - insights.citeline.com

01:00 AM
pulisher
Apr 25, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

Apr 25, 2025
pulisher
Apr 17, 2025

Trend Tracker for (ITCI) - news.stocktradersdaily.com

Apr 17, 2025
pulisher
Apr 16, 2025

Zynext Ventures Invests in Feldan Therapeutics to Drive Innovation in Intracellular Drug Delivery - Yahoo Finance

Apr 16, 2025
pulisher
Apr 15, 2025

JNJ Tops Q1 Earnings, Ups '25 Sales View to Include Intra-Cellular Deal - TradingView

Apr 15, 2025
pulisher
Apr 15, 2025

Johnson & Johnson Reports Q1 2025 Results - BioSpace

Apr 15, 2025
pulisher
Apr 08, 2025

Intra-Cellular Therapies’ SWOT analysis: acquisition shifts landscape for psychiatric drug stock - Investing.com Canada

Apr 08, 2025
pulisher
Apr 08, 2025

Intra-Cellular Therapies’ SWOT analysis: acquisition shifts landscape for psychiatric drug stock By Investing.com - Investing.com South Africa

Apr 08, 2025
pulisher
Apr 05, 2025

Johnson & Johnson - drugdiscoverytrends.com

Apr 05, 2025
pulisher
Apr 04, 2025

Johnson & Johnson Expects Lower Earnings Impact From Intra-Cellular Therapies Acquisition - MSN

Apr 04, 2025
pulisher
Apr 03, 2025

J&J acquires Intra-Cellular Therapies in multi-billion-dollar deal - ROI-NJ

Apr 03, 2025
pulisher
Apr 03, 2025

J&J to complete acquisition of Intra-Cellular Therapies - Medical Buyer

Apr 03, 2025
pulisher
Apr 03, 2025

JnJ closes Intra-Cellular Therapies acquisition - Medical Dialogues

Apr 03, 2025
pulisher
Apr 02, 2025

JNJ forecasts 2025 profit dilution from Intra-Cellular deal, sets closing date - MSN

Apr 02, 2025
pulisher
Apr 02, 2025

Demystifying Intra-Cellular Therapies: Insights From 6 Analyst Reviews - Benzinga

Apr 02, 2025
pulisher
Apr 02, 2025

Intra-Cellular Therapies acquired by Johnson & Johnson for $14.6 billion - Investing.com South Africa

Apr 02, 2025
pulisher
Apr 02, 2025

Intra-Cellular Therapies Completes Merger with Johnson & Johnson - TipRanks

Apr 02, 2025
pulisher
Apr 02, 2025

Johnson & Johnson acquires Intra-Cellular Therapies By Investing.com - Investing.com South Africa

Apr 02, 2025
pulisher
Apr 02, 2025

Stock Of The Day: Will Johnson & Johnson Rally? The Sell-Off May Have Ended - Benzinga

Apr 02, 2025
pulisher
Apr 02, 2025

Johnson & Johnson Acquires Intra-Cellular Therapies - citybiz

Apr 02, 2025
pulisher
Apr 02, 2025

Johnson & Johnson Closes Landmark Intra-Cellular Therapies, Inc. Acquisition to Solidify Neuroscience Leadership - BioSpace

Apr 02, 2025
pulisher
Apr 02, 2025

Johnson & Johnson Completes Intra-Cellular Therapies Purchase - MarketScreener

Apr 02, 2025
pulisher
Apr 02, 2025

JNJ Completes Acquisition Of Intra-Cellular Therapies - Nasdaq

Apr 02, 2025
pulisher
Apr 02, 2025

Johnson & Johnson acquires Intra-Cellular Therapies - Investing.com

Apr 02, 2025
pulisher
Apr 02, 2025

Johnson & Johnson completes Intra-Cellular Therapies acquisition, sees dilution - TipRanks

Apr 02, 2025
pulisher
Apr 02, 2025

Johnson & Johnson (JNJ) Closes Intra-Cellular Therapies, Inc. (ITCI) Acquisition - StreetInsider

Apr 02, 2025
pulisher
Apr 02, 2025

Johnson & Johnson Expands Its Horizon With Intra-Cellular Therapies Deal - Finimize

Apr 02, 2025
pulisher
Apr 02, 2025

Johnson & Johnson Announces Expected Closing Date for Intra-Cellular Acquisition - BioSpace

Apr 02, 2025
pulisher
Apr 01, 2025

Johnson & Johnson Set To Complete Acquisition Of Intra-Cellular Therapies By April 2, 2025 - Nasdaq

Apr 01, 2025
pulisher
Apr 01, 2025

Johnson & Johnson to finalize Intra-Cellular buyout By Investing.com - Investing.com Canada

Apr 01, 2025
pulisher
Apr 01, 2025

Johnson & Johnson to finalize Intra-Cellular buyout - Investing.com

Apr 01, 2025
pulisher
Apr 01, 2025

Johnson & Johnson Intra-Cellular acquisition to accelerate FY25 sales by 0.8% - TipRanks

Apr 01, 2025
pulisher
Apr 01, 2025

Johnson & Johnson (JNJ) Sets April 2nd as Expected Closing Date for Intra-Cellular Acquisition - StreetInsider

Apr 01, 2025
pulisher
Apr 01, 2025

Intra-cellular Therapeutics Surges to 322nd in Trading Volume Ranking with 3.36 Billion Shares Exchanged - AInvest

Apr 01, 2025
pulisher
Mar 31, 2025

(ITCI) On The My Stocks Page - news.stocktradersdaily.com

Mar 31, 2025
pulisher
Mar 28, 2025

Intra-cellular Therapies Surges to 340th in Daily Rankings with 2.46 Billion Turnover - AInvest

Mar 28, 2025
pulisher
Mar 27, 2025

Intra-Cellular Therapies Stock Hits All-Time High of $131.79 By Investing.com - Investing.com South Africa

Mar 27, 2025
pulisher
Mar 27, 2025

Intra-Cellular Therapies Shareholders Approve Johnson & Johnson Merger - Investing.com

Mar 27, 2025
pulisher
Mar 27, 2025

Intra-Cellular Therapies Shareholders Approve Johnson & Johnson Merger By Investing.com - Investing.com Australia

Mar 27, 2025
pulisher
Mar 27, 2025

Beam Therapeutics (BEAM) Down 21.4% Since Last Earnings Report: Can It Rebound? - Yahoo Finance

Mar 27, 2025
pulisher
Mar 27, 2025

Intra-Cellular Therapies Stock Hits All-Time High of $131.79 - Investing.com

Mar 27, 2025
pulisher
Mar 27, 2025

Intra-Cellular Therapies: These Are 5 Critical Challenges Threatening Its Expansion Plans! - Smartkarma

Mar 27, 2025
pulisher
Mar 19, 2025

Intra-Cellular Therapies announces proxy statement supplement By Investing.com - Investing.com South Africa

Mar 19, 2025
pulisher
Mar 18, 2025

Intra-Cellular Therapies announces proxy statement supplement - Investing.com

Mar 18, 2025
pulisher
Mar 18, 2025

Intra-Cellular Therapies stockholder filed lawsuit against co, board in NY Supreme Court - Marketscreener.com

Mar 18, 2025
pulisher
Mar 18, 2025

Intra-Cellular Therapies Stock Hits All-Time High of $131.47 By Investing.com - Investing.com UK

Mar 18, 2025
pulisher
Mar 18, 2025

Intra-Cellular Therapies (ITCI): Among the Best Biotech Stocks to Buy According to Billionaires - Yahoo Finance

Mar 18, 2025

Intra Cellular Therapies Inc Stock (ITCI) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$294.60
price up icon 0.26%
$109.68
price up icon 2.90%
$16.19
price up icon 3.65%
$8.65
price up icon 2.13%
$108.74
price up icon 2.66%
$9.75
price up icon 2.96%
Cap:     |  Volume (24h):